Moysan F, van Hoegaerden M, Cooper R W, Bhatia S C, Poltera A A, Striebel H P, Ivanoff B
Centre International de Recherches Médicales Franceville (CIRMF), Franceville, Gabon.
Trop Med Parasitol. 1988 Mar;39(1):35-9.
CGP 20,376, a benzthiazole and new antifilarial agent, was investigated at CIRMF in eight wild born chimpanzees naturally infected with Dipetalonema vanhoofi. Single oral doses (3.75, 7.5, 11 and 15 mg/kg) were administered. Drug levels during the first hour after administration were assessed in seven chimpanzees at 10 minute intervals in the blood. Levels of unchanged drug (CGP 20,376) were higher than those of its metabolite (CGP 20,308). However, there was considerable variation between individuals, although the results for each animal were consistent. Because of investigational limitations a complete drug profile could not be established. Unsheathed microfilariae of D. vanhoofi were monitored during the first hour following drug administration in seven chimpanzees. In five the microfilaraemia dropped to low counts within 10 minutes and remained below the initial values for the next 50 minutes while in two other chimpanzees it showed a more irregular reduction. Periodic microfilarial counts over the next 20 months, at roughly 30 day intervals, showed that three chimpanzees, treated with 7.5, 11 and 15 mg/kg respectively, remained free of circulating microfilariae from Day 1 to Day 600, the chimpanzee treated with 3.75 mg/kg remained microfilaremic and, in three chimpanzees low numbers of microfilariae reappeared within one year, whereas in the remaining ape they reappeared after one year. No major clinical adverse effects were observed, but liver function tests showed mild reversible changes at the 11 and 15 mg/kg doses. CGP 20,376 was therefore microfilaricidal, except for the lowest dose, and it was possibly macrofilaricidal in those chimpanzees which remained free of microfilariae for 600 days. Clinically CGP 20,376 was well tolerated.(ABSTRACT TRUNCATED AT 250 WORDS)
CGP 20,376是一种苯并噻唑类新型抗丝虫药,在国际医学研究中心(CIRMF)对8只自然感染范氏双瓣线虫的野生黑猩猩进行了研究。给予单次口服剂量(3.75、7.5、11和15毫克/千克)。给药后第一小时内,对7只黑猩猩每隔10分钟进行一次血液中的药物水平评估。未变化的药物(CGP 20,376)水平高于其代谢物(CGP 20,308)的水平。然而,个体之间存在相当大的差异,尽管每只动物的结果是一致的。由于研究限制,无法建立完整的药物概况。在给药后的第一小时内,对7只黑猩猩体内的范氏双瓣线虫无鞘微丝蚴进行了监测。5只黑猩猩的微丝蚴血症在10分钟内降至低水平,并在接下来的50分钟内保持在初始值以下,而另外2只黑猩猩的微丝蚴血症下降则更为不规则。在接下来的20个月里,大约每隔30天进行一次周期性微丝蚴计数,结果显示,分别用7.5、11和15毫克/千克治疗的3只黑猩猩从第1天到第600天均未出现循环微丝蚴,用3.75毫克/千克治疗的黑猩猩仍有微丝蚴血症,3只黑猩猩在一年内重新出现少量微丝蚴,而其余一只黑猩猩在一年后重新出现微丝蚴。未观察到重大临床不良反应,但肝功能测试显示,在11和15毫克/千克剂量下出现了轻度可逆性变化。因此,CGP 20,376除最低剂量外具有杀微丝蚴作用,对于那些600天内无微丝蚴的黑猩猩可能具有杀成虫作用。临床上,CGP 20,376耐受性良好。(摘要截短为250字)